Financial Survey: Ocata Therapeutics (OCAT) vs. Its Rivals

Ocata Therapeutics (NASDAQ: OCAT) is one of 289 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Ocata Therapeutics to similar companies based on the strength of its valuation, risk, analyst recommendations, profitability, dividends, earnings and institutional ownership.

Insider and Institutional Ownership

49.8% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 16.8% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.


This table compares Ocata Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ocata Therapeutics -4,564.66% -103.02% -46.18%
Ocata Therapeutics Competitors -5,322.24% -84.37% -35.66%

Valuation and Earnings

This table compares Ocata Therapeutics and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Ocata Therapeutics N/A N/A -12.10
Ocata Therapeutics Competitors $290.27 million $35.99 million 56.39

Ocata Therapeutics’ competitors have higher revenue and earnings than Ocata Therapeutics. Ocata Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Ocata Therapeutics and its competitors, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ocata Therapeutics 0 0 0 0 N/A
Ocata Therapeutics Competitors 954 3405 11909 239 2.69

As a group, “Bio Therapeutic Drugs” companies have a potential upside of 40.74%. Given Ocata Therapeutics’ competitors higher probable upside, analysts plainly believe Ocata Therapeutics has less favorable growth aspects than its competitors.


Ocata Therapeutics competitors beat Ocata Therapeutics on 7 of the 8 factors compared.

About Ocata Therapeutics

Ocata Therapeutics, Inc., formerly Advanced Cell Technology, Inc., is a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. The Company’s advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. The Company is also developing several pre-clinical terminally differentiated-cell therapies for the treatment of other ocular disorders. Additionally, it has a number of pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders.

Receive News & Ratings for Ocata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocata Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply